Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.39 |
| ▸ | ALPL | P05186 | 4/20 | 0.38 |
| ▸ | TLR8 | Q9NR97 | 5/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | ALPG | P10696 | 1/20 | 0.34 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | MARS1 | P56192 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5773966 | 0.89 | SIRT2 (0.39) | SIRT2TLR8RAB9A | |
| SCHEMBL5775506 | 0.85 | AHR (0.36) | CYP1A2NPC1CYP2C19RAB9ACYP2C9 | |
| SCHEMBL5774165 | 0.83 | ATM (0.39) | SIRT2TLR8NPC1RAB9AL3MBTL1 | |
| SCHEMBL5774926 | 0.81 | TP53 (0.44) | ALPLSMN1; SMN2 | |
| SCHEMBL5774173 | 0.80 | SIRT2 (0.52) | SIRT2TLR8NPC1CYP2C19RAB9A | |
| SCHEMBL5774842 | 0.78 | TDO2 (0.44) | SIRT2TLR8CYP1A2 | |
| SCHEMBL5773924 | 0.77 | MAPT (0.44) | ALPLCYP1A2CYP2C19CYP3A4 | |
| SCHEMBL5771241 | 0.77 | SIRT2 (0.39) | SIRT2TLR8 | |
| SCHEMBL5771560 | 0.76 | SIRT2 (0.40) | SIRT2TLR8NPC1RAB9A | |
| SCHEMBL5770999 | 0.76 | SIRT2 (0.40) | SIRT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060084690-A1 | Isoxazole derivatives | MOMOSE YU | 2006-04-20 | — | — | US | disclosed |
| US-7022725-B2 | Isoxazole derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-04-04 | — | — | US | disclosed |
| US-20040048908-A1 | Isoxazole derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-03-11 | — | — | US | disclosed |
| EP-1340749-A1 | ISOXAZOLE DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 2003-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084690-A1 | Isoxazole derivatives | INSR, GPR119, INSRR | SIRT2 1426/4885ALPL 802/4885TLR8 2618/4885 |
| US-20040048908-A1 | Isoxazole derivatives | GPR119, INSR, IRS1 | SIRT2 738/4885ALPL 601/4885TLR8 3077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.